What is claimed is:

1. A compound of Formula I:



I

or a pharmaceutically acceptable salt thereof, wherein:

R^1 is selected from 1-ethyl-1H-imidazol-4-yl and 4-methyl-2H-1,2,3-triazol-2-yl; and

R^2 is selected from (1R,5S)-3-(tetrahydro-2H-pyran-4-yl)-3-azabicyclo[3.1.0]hexan-1-yl and 2-methyl-2-azabicyclo[2.2.2]octane.

2. The compound of claim 1, wherein the compound of Formula I is selected from:

2-(1-ethyl-1H-imidazol-4-yl)-5-(6-methyl-7-(4-((1R,5S)-3-(tetrahydro-2H-pyran-4-yl)-3-azabicyclo[3.1.0]hexan-1-yl)phenyl)imidazo[1,2-b]pyridazin-3-yl)-1,8-naphthyridine;

2-(4-(3-(7-(1-ethyl-1H-imidazol-4-yl)-1,8-naphthyridin-4-yl)-6-methylimidazo[1,2-b]pyridazin-7-yl)benzyl)-2-azabicyclo[2.2.2]octane; and

2-(4-(6-methyl-3-(7-(4-methyl-2H-1,2,3-triazol-2-yl)-1,8-naphthyridin-4-yl)imidazo[1,2-b]pyridazin-7-yl)benzyl)-2-azabicyclo[2.2.2]octane;

or a pharmaceutically acceptable salt thereof.

3. The compound of claim 1, wherein the compound is 2-(1-ethyl-1H-imidazol-4-yl)-5-(6-methyl-7-(4-((1R,5S)-3-(tetrahydro-2H-pyran-4-yl)-3-azabicyclo[3.1.0]hexan-1-yl)phenyl)imidazo[1,2-b]pyridazin-3-yl)-1,8-naphthyridine, or a pharmaceutically acceptable salt thereof.

4. The compound of claim 1, wherein the compound is 2-(4-(3-(7-(1-ethyl-1H-imidazol-4-yl)-1,8-naphthyridin-4-yl)-6-methylimidazo[1,2-b]pyridazin-7-yl)benzyl)-2-azabicyclo[2.2.2]octane, or a pharmaceutically acceptable salt thereof.

5. The compound of claim 1, wherein the compound is 2-(4-(6-ethyl-3-(7-(4-methyl-2H-1,2,3-triazol-2-yl)-1,8-naphthyridin-4-yl)imidazo[1,2-b]pyridazin-7-yl)benzyl)-2-azabicyclo[2.2.2]octane, or a pharmaceutically acceptable salt thereof.

6. A pharmaceutical composition comprising a compound of any one of claims 1-5, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier or excipient.

7. A method of inhibiting ALK2 activity, comprising contacting ALK2 with a compound of any one of claims 1-5, or a pharmaceutically acceptable salt thereof.

8. A method of inhibiting ALK2 activity, comprising administering to a patient a compound of any one of claims 1-5, or a pharmaceutically acceptable salt thereof.

9. A method of treating a disease or disorder associated with expression or activity of ALK2, wherein said method comprises administering to a patient in need thereof a therapeutically effective amount of a compound of any one of claims 1-5, or a pharmaceutically acceptable salt thereof.

10. A method of treating cancer in a patient, wherein said method comprises administering to the patient a therapeutically effective amount of a compound of any one of claims 1-5, or a pharmaceutically acceptable salt thereof.

11. A method of treating a cancer in a patient, wherein said method comprises administering to the patient a therapeutically effective amount of a compound of any one of claims 1-5, or a pharmaceutically acceptable salt thereof, in combination with a further therapeutic agent.

12. The method of claim 11, wherein the therapeutic agent is a Janus kinase inhibitor.

13. The method of claim 12, wherein the therapeutic agent is ruxolitinib.

14. A method of treating myeloproliferative diseases in a patient, wherein said method comprises administering to the patient a therapeutically effective amount of a compound of any one of claims 1-5, or a pharmaceutically acceptable salt thereof, and a Janus kinase inhibitor, or a pharmaceutically acceptable salt thereof.

15. A method of treating myeloproliferative diseases in a patient, wherein said method comprises administering to the patient a therapeutically effective amount of a compound of any one of claims 1-5, or a pharmaceutically acceptable salt thereof, and ruxolitinib, or a pharmaceutically acceptable salt thereof.

16. A compound which is 2-(4-Methyl-2H-1,2,3-triazol-2-yl)-5-(6-methyl-7-(4-((1S,5R)-3-(tetrahydro-2H-pyran-4-yl)-3-azabicyclo[3.1.0]hexan-1-yl)phenyl)imidazo[1,2-b]pyridazin-3-yl)-1,8-naphthyridine, or a pharmaceutically acceptable salt thereof.

17. A pharmaceutical composition comprising a compound of claim 16, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier or excipient.

18. A method of inhibiting ALK2 activity, comprising contacting ALK2 with a compound of claim 16, or a pharmaceutically acceptable salt thereof.

19. A method of treating a disease or disorder associated with expression or activity of ALK2, wherein said method comprises administering to a patient in need thereof a therapeutically effective amount of a compound of claim 16, or a pharmaceutically acceptable salt thereof.

20. A method of treating cancer in a patient, wherein said method comprises administering to the patient a therapeutically effective amount of a compound of claim 16, or a pharmaceutically acceptable salt thereof.